Los puntos clave no están disponibles para este artículo en este momento.
Because of a warning from the FDA, 23andMe has stopped marketing its personal genome service. Now, a dialogue about key issues in genomic testing could result in clear standards for the industry, including requirements for informed consent and disclosure of results.
Annas et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: